In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Anteris Technologies Global Corp., with a price target of $15.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Josh Jennings has given his Buy rating due to a combination of factors that highlight the promising potential of Anteris Technologies Global Corp.’s DurAVR system. The recent presentation of 30-day data from 100 patients at the London Valves meeting demonstrated high technical and device success rates, along with favorable hemodynamic outcomes. These results, which include low rates of prosthesis-patient mismatch (PPM) and no valve-related mortality, bolster confidence in the ongoing pivotal study of DurAVR.
Furthermore, the data showed a mean pressure gradient of 8.2 mmHg and a mean effective orifice area (EOA) of 2.2 cm², indicating strong performance metrics. The low incidence of new permanent pacemaker implantation and the absence of moderate or severe paravalvular leak (PVL) further support the system’s efficacy. These findings, along with the positive one-year data previously presented, reinforce the potential of DurAVR as a differentiated transcatheter aortic valve replacement (TAVR) system, justifying the Buy rating.
According to TipRanks, Jennings is a 2-star analyst with an average return of 0.1% and a 47.49% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Medtronic, TransMedics Group, and Boston Scientific.
In another report released on November 13, Lake Street also reiterated a Buy rating on the stock with a $20.00 price target.